Zimmer Biomet Holdings, INC 8-K filings

Zimmer Biomet announced second quarter 2026 financial results, with net sales increasing 4.8% and the company raising its full-year guidance.

Zimmer Biomet Holdings, Inc. has entered into new five-year and 364-day revolving credit agreements totaling $2.75 billion, replacing previous facilities.

Zimmer Biomet shareholders re-elected ten directors and ratified the appointment of PricewaterhouseCoopers LLP at the 2026 annual meeting.

Zimmer Biomet announced an increased share repurchase program, now targeting up to $1 billion in fiscal year 2026, a $250 million rise from previous expectations.

Zimmer Biomet Holdings, Inc. announced the resignation of its Chief Financial Officer, Suketu Upadhyay, effective April 28, 2026, with Paul Stellato appointed as interim CFO.

Zimmer Biomet announced first quarter 2026 net sales of $2.087 billion, a 9.3% increase, and raised its full-year adjusted EPS guidance.

Zimmer Biomet announced robust fourth-quarter and full-year 2025 financial results, exceeding initial commitments, and authorized a new $1.5 billion stock repurchase program.

Zimmer Biomet Holdings, Inc. announced the resignation of Mark Bezjak, a named executive officer, effective January 16, 2026, to pursue a new business opportunity.

Zimmer Biomet reported strong third-quarter net sales growth of 9.7% to $2.001 billion, driven by U.S. business strength and new product adoption, while narrowing its full-year 2025 revenue guidance.

Zimmer Biomet completed its acquisition of Monogram Technologies, significantly expanding its orthopedic robotics portfolio with semiand fully autonomous technologies.

Zimmer Biomet Holdings, Inc. announced the issuance of CHF 600 million in new senior unsecured debt securities across two tranches.

Zimmer Biomet reported solid second quarter 2025 financial results, with increased net sales and adjusted earnings per share, leading to a tightened revenue outlook and raised full-year adjusted EPS guidance.

Zimmer Biomet Holdings, Inc. has entered into a definitive agreement to acquire Monogram Technologies Inc. for approximately $168 million, aiming to expand its orthopedic robotics portfolio with semiand fully-autonomous AI-driven surgical systems.

Zimmer Biomet Holdings, Inc. has successfully entered into new five-year and 364-day revolving credit agreements totaling $2.5 billion, replacing its previous facilities to support general corporate purposes and strategic growth initiatives.

Zimmer Biomet Holdings, Inc. shareholders have approved key corporate governance changes, including an expanded stock incentive plan and an amendment to limit officer liability, at their annual meeting on May 29, 2025.

Zimmer Biomet Holdings, Inc. announced the appointment of Kevin Thornal to the newly-created position of Group President, Global Businesses and the Americas, effective July 1, 2025, signaling a strategic move to enhance commercial execution and global business strategy.

Zimmer Biomet reports a 1.1% increase in first quarter net sales, driven by growth in U.S. Hips and the acquisition of Paragon 28, and updates its full-year 2025 revenue and earnings per share guidance.

Zimmer Biomet has completed its acquisition of Paragon 28, a medical device company specializing in foot and ankle orthopedics, to strengthen its position in this high-growth segment.

Zimmer Biomet announced that Christopher Begley will retire as Chairman, with Ivan Tornos succeeding him and Michael Farrell appointed as Lead Independent Director, effective May 29, 2025.

Zimmer Biomet Holdings issues $1.75 billion in new notes across three series to finance the Paragon 28 merger and for general corporate purposes.

Zimmer Biomet Holdings, Inc. has entered into an underwriting agreement for a public offering of $1.75 billion in aggregate principal amount of notes due in 2027, 2030, and 2035.

Zimmer Biomet announced positive fourth quarter and full-year 2024 financial results, highlighted by increased net sales and earnings per share, and revealed a definitive agreement to acquire Paragon 28, Inc.

Zimmer Biomet has agreed to acquire Paragon 28 for $13 per share in cash plus a contingent value right, marking a significant move in the orthopedic sector.

Zimmer Biomet is set to acquire Paragon 28, a foot and ankle orthopedic company, for an upfront payment of $13.00 per share in cash, plus a contingent value right, in a deal valued at approximately $1.1 billion.

Zimmer Biomet has completed the issuance of €700 million in 3.518% notes due in 2032, with interest payable annually.

Zimmer Biomet has entered into an underwriting agreement for a public offering of $700 million in notes due 2032, with the sale expected to close on November 20, 2024.

Zimmer Biomet announced a 4.0% increase in third-quarter net sales and updated its full-year financial guidance, narrowing the range for revenue growth and adjusted diluted EPS.

Zimmer Biomet has successfully issued $700 million in new debt securities with a 5.200% interest rate, maturing in 2034.

Zimmer Biomet has entered into an agreement to issue $700 million in 5.200% notes due in 2034.

Zimmer Biomet has filed an 8-K to recast certain financial information from its 2023 annual report due to revisions in how segment operating profits are measured.